Genmab — September 2019

[E_L]

Nasdaq opening bell https://twitter.com/Genmab/status/1171151562867167240

[bibob]

De er kommet i fint selskab E L.

[E_L]

[bibob]

Det kan være det var det emissionen skulle bruges til. Vi ved jo det koster når man ringer med klokken på værtshus.

[polle1]

Why are we not invited to join them in New York, EL ?

[polle1]

I så fald endnu en årsag til at vi burde være i NY, bibob

[E_L]

Were you not invited Polle??? I am on Times Square now with bibob

[bibob]

Yes.

[E_L]

Novartis building up some excitement around ECTRIMS https://ml-eu.globenewswire.com/Resource/Download/f8696a1f-26cb-4cf8-a49d-aa4d24f0c23f

[E_L]

I wonder if Jan is in NY then for the Morgan Stanley Global Healthcare Conference which is now; we did not get any news on that , did we?

[GeorgeBest]

Are you invited E L? I am at the conference this afternoon lisening to Jan

[E_L]

hahaha good one

[bibob]

FirstWord. Physician views snap poll results : If efficacy data are compelling, Novartis Ofatumumab should provide a tangible threat to Roche's Ocrevus.

[GeorgeBest]

Cross fingers for compelling data:-)

[bibob]

[Plimsoller]

Kommer der data i morgen?

[Bulder]

bibob, kan du læse snap poll resultatet?

[bibob]

Jeg prøver at sætte noget ind Bulder.

[royal]

Mon det er Jan med klokken? It is our pleasure to ring the Nasdaq Opening Bell tomorrow. A livestream of the event will be available at 9:20 AM EDT on September 10 from the Nasdaq Facebook page: facebook.com/nasdaq

[bibob]

Afsked prospectively about the future threat of Ofatumumab Roche has suggested that it has experienced minimal pushback in Ocrevus adoption due to the dosing regimen; twice yerly IV administration closely track the typical rate of patient/psysician interactions the Company says. However feedback from the 60 neurologiske ( based in the US , France , Germany and UK ) we snap- polled suggest adoption of Ocrevus would have been even faster If administered in a different way with just under a third